Significance of the detection of TIM-3 and FOXJ1 in prostate cancer.
This study sought to identify and evaluate the diagnostic value of T-cell immunoglobulin domain and mucin-3 (TIM-3) and forkhead box protein J1 (FOXJ1) expression in prostate cancer. Thirty prostate cancer patients and 30 individuals with benign prostatic hyperplasia diagnosed and treated at the Central Hospital of Enshi Autonomous Prefecture between March 2016 and October 2016 were selected for this study. The expression of TIM-3 and FOXJ1 in patient prostate tissue was detected by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR). TIM-3 and FOXJ1 expression diagnostic value for prostate cancer was analyzed by using the receiver operating curve (ROC). Expression of TIM-3 and FOXJ1 in prostate cancer tissues was significantly higher than those in normal prostate tissues (p<0.05), and expression of TIM-3 and FOXJ1 in prostate cancer tissues were positively correlated with Gleason score and clinical stage (p<0.05). However, the expression of the two proteins were not correlated with age, PSA level, pathological type, or the maximum tumor diameter (p>0.05). ROC analysis indicated that TIM-3 mRNA could be used to diagnose prostate cancer with an accuracy of 0.824, a sensitivity of 85.9% and a specificity of 91.2%, while the diagnostic accuracy, sensitivity, and specificity of FOXJ1 were 0.843, 86.3%, and 82.7%, respectively. TIM-3 and FOXJ1 exhibited abnormally high expression levels in prostate cancer, and can therefore be important indicators for the diagnosis of this disease.